Skip to main content

Advertisement

Log in

Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to test the reliability of the Swedish version of the Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ) administrated throughout a self-reported mobile phone-based system, a pilot study.

Methods

Twenty-three patients from two university hospitals and two regional hospitals who had been treated with oxaliplatin were included through purposive sampling between autumn 2013 to autumn 2014. A test-retest was performed through a mobile phone-based system, with a recall period of 1 h to determine the reliability of the questionnaire.

Results

Internal consistency was strong for the three domains of the scale (α > 0.840). The statistical analyses for the test-retest indicated that the OANQ was stable. Intraclass correlation (ICC) for symptom items and effect on daily activities items showed an overall excellent reproducibility at 69 and 83 %, respectively. The weighted kappa for symptom items and daily activities items showed an overall almost perfect agreement at 59 and 52 %, respectively. A paired samples t test did not reveal any significant differences between the two measures.

Conclusions

The OANQ was tested and considered a reliable assessment for capturing the oxaliplatin-induced peripheral neurotoxicity (OIPN) in patients receiving oxaliplatin. However, further reliability testing of the OANQ is needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grenon N, Chan J (2009) Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses. Clin J Oncol Nurs 13(3):285–296. doi:10.1188/09.CJON.285-296

    Article  PubMed  Google Scholar 

  2. Velasco R, Bruna J, Briani C et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Pschiatry 85(4):392–398. doi:10.1136/jnnp-2013-305334

    Article  Google Scholar 

  3. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116. doi:10.1200/JCO.2008.20.6771

    Article  PubMed  Google Scholar 

  4. Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21(12):3307–3313. doi:10.1007/s00520-013-1905-5

    Article  PubMed  Google Scholar 

  5. Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205–2211

    Article  PubMed  CAS  Google Scholar 

  6. Tofthagen C, McAllister RD, McMillan SC (2011) Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs 15(2):182–188. doi:10.1188/11.CJON.182-188

    Article  PubMed  Google Scholar 

  7. Park BS, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437. doi:10.3322/caac.21204

    Article  PubMed  Google Scholar 

  8. Kidwell K, Yothers G, Ganz P et al (2012) Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer. Cancer 118(22):5614–5622. doi:10.1002/cncr.27593

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13–16

    Article  PubMed  CAS  Google Scholar 

  10. Vatandoust A, Joshi R, Pittman KB et al (2014) A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer 22(2):513–518

    Article  PubMed  Google Scholar 

  11. Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C et al (2014) Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol 89(1):166–178. doi:10.1016/j.critrevonc.2013.08.009

    Article  PubMed  Google Scholar 

  12. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507–1515. doi:10.1016/j.ejca.2008.04.018

    Article  PubMed  CAS  Google Scholar 

  13. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. doi:10.1200/JCO.2013.54.0914

    Article  PubMed  CAS  Google Scholar 

  14. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Larsen ME, Rowntree J, Young AM et al (2008) Chemotherapy side-effect management using mobile phones. Conf Proc IEEE Eng Med Biol Soc 2008:5152–5155. doi:10.1109/IEMBS.2008.4650374

    PubMed  Google Scholar 

  16. McCann L, Maguire R, Miller M, Kearney N (2009) Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care 18(2):156–164. doi:10.1111/j.1365-2354.2008.00938.x

    Article  CAS  Google Scholar 

  17. Mirkovic J, Kaufman DR, Ruland CM (2014) Supporting cancer patients in illness management: usability evaluation of a mobile app. JMIR Mhealth Uhealth 2(3):e33. doi:10.2196/mhealth.3359

    Article  PubMed  PubMed Central  Google Scholar 

  18. Maguire R, McCann L, Miller M, Kearney N (2008) Nurses’ perceptions and experiences of using of a mobile-phone-based advanced symptom management system (AsyMS©) to monitor and manage chemotherapy-related toxicity. Eur J Oncol Nurs 12(4):380–386. doi:10.1016/j.ejon.2008.04.007

    Article  PubMed  CAS  Google Scholar 

  19. Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479–494. doi:10.1016/j.ejca.2009.12.008

    Article  PubMed  CAS  Google Scholar 

  20. Kopec JA, Land SR, Cecchini RS et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4(8):W1–W8

    Google Scholar 

  21. Leonard GD, Wright MA, Quinn MG et al (2005) Survey of oxaliplatin-associated neurotoxicity using and interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 16(5):16. doi:10.1186/1471-2407-5-116

    Google Scholar 

  22. Driessen CML, Kleine-Bolt KME, Vingerhoets AJJM, Mols F, Vreugdenhil G (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881. doi:10.1007/s00520-011-1336-0

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Cathomas R, Köberle D, Ruhstaller T et al (2010) Heated (37 °C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 18(10):1263–1270. doi:10.1007/s00520-009-0740-1

    Article  PubMed  Google Scholar 

  24. Drott JE, Starkhammar H, Börjesson S, Berterö C (2014) Oxaliplatin induced neurotoxicity among patients with colorectal cancer: documentation in medical records—a pilot study. Open J Nurs 4:265–274. doi:10.4236/ojn.2014.44031

    Article  Google Scholar 

  25. Brislin RW (1970) Back-translation for cross-cultural research. J Cross-Cult Psychol 1(3):185–216. doi:10.1177/135910457000100301

    Article  Google Scholar 

  26. Acquadro C, Conway K, Giroudet C, Mear I (2012) Linguistic validation manual for health outcome assessments. MAPI Institute, Lyon

    Google Scholar 

  27. Mokkink LB, Terweea CB, Patrick DL et al (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 63(7):737–745. doi:10.1016/j.jclinepi.2010.02.006

    Article  PubMed  Google Scholar 

  28. Rosner B (2011) Fundamentals of biostatistics. Brooks, Boston

    Google Scholar 

  29. Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360–363

    PubMed  Google Scholar 

  30. Polit DF (2014) Getting serious about test-retest reliability: a critique of retest research and some recommendations. Qual Life Res 23(6):1713–1720. doi:10.1007/s11136-014-0632-9

    Article  PubMed  Google Scholar 

  31. Field A (2013) Discovering statistics using IBM SPSS statistics: and sex and drugs and rock ‘n’ roll, 4th edn. Sage, Los Angeles

    Google Scholar 

  32. Polit DF, Beck CT (2012) Nursing research, generating and assessing evidence for nursing practice, 9th edn. Lippincott Williams & Wilkins, Philadelphia

    Google Scholar 

  33. Berger A, Edwards Neumark D, Chamberlain J (2007) Enhancing recruitment and retention in randomized controlled clinical trials of cancer symptom management. Oncol Nurs Forum 34(2):e17–e22

    Article  PubMed  Google Scholar 

  34. Ganz PA, Land SR, Antonio C et al (2009) Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv 3(3):137–147. doi:10.1007/s11764-009-0093-2

    Article  PubMed  PubMed Central  Google Scholar 

  35. Paul C, Courtney R, Sanson-Fisher R et al (2014) A randomized controlled trial of the effectiveness of a pre-recruitment primer letter to increase participation in a study of colorectal screening and surveillance. BMC Med Res Methodol. 14:44 http://biomedcentral.com/1471-2288/14/44

  36. Hobart JC, Cano SJ, Warner TT, Thompson AJ (2012) What sample sizes for reliability and validity studies in neurology? J Neurol 259(12):2681–2694. doi:10.1007/s00415-012-6570-y

    Article  PubMed  Google Scholar 

  37. Stull DE, Kline Leidy N, Parasuraman B, Chassany O (2009) Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 25(4):929–942. doi:10.1185/03007990902774765

    Article  PubMed  Google Scholar 

  38. Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. doi:10.1016/j.pain.2014.09.020

    Article  PubMed  Google Scholar 

  39. Bakitas M (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331

    Article  PubMed  Google Scholar 

  40. Bennett BK, Park SB, Lin CSY, Friedlander ML, Kiernan MC, Goldstein D (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20(11):2959–2967

    Article  PubMed  Google Scholar 

  41. Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999–2007. doi:10.1007/s00520-014-2242-z

    Article  PubMed  CAS  Google Scholar 

  42. Velikova G, Keding A, Harley C et al (2010) Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomized controlled trial. Eur J Cancer 46(13):2381–2388. doi:10.1016/j.ejca.2010.04.030

    Article  PubMed  Google Scholar 

  43. Dickinson R, Hall S, Sinclair JE, Bond C, Murchie P (2014) Using technology to deliver cancer follow-up: a systematic review. BMC Cancer 14:(1)311 http://biomedcentral.com/1471-2407/14/311

  44. Børøsund E, Ruland CM, Moore S, Ekstedt M (2014) Nurses’ experiences of using an interactive tailored patient assessment tool one year past implementation. Int J Med Inform 83(7):e23–e34. doi:10.1016/j.ijmedinf.2013.10.010

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank all patients for their participation in the study. We would also like to thank Gun Skire at CQ for the technical support and Karl Wallin at LARC and Kristofer Årestedt at IMH for the statistical support and discussions. We thank all nurses in the oncology clinics who had contributed to the recruitment of patients. We also are grateful to the Division of Nursing Science at the Department of Medical and Health Sciences for the financial support.

Conflict of interest

The authors declare that they have no competing interests.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Drott.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gustafsson, E., Litström, E., Berterö, C. et al. Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study. Support Care Cancer 24, 747–754 (2016). https://doi.org/10.1007/s00520-015-2838-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2838-y

Keywords

Navigation